We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GSIW:NASDAQGarden Stage Limited Analysis

Data as of 2026-06-13 - not real-time

$30.01

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The technical stack shows a modestly bullish alignment, with the 20‑day SMA (≈30.3) sitting above both the 50‑day (≈28.1) and 200‑day (≈27.4) averages, and the RSI at about 54 indicating a near‑neutral stance. However, the MACD tells a different story: the histogram is negative (‑0.136) and the signal is labeled "bearish," suggesting an imminent pull‑back despite the overall trend direction being listed as bullish. Volume is stable but extremely low (average 10‑day volume ≈4050 versus today’s 127), and the 30‑day volatility spikes at 61%, while the beta of roughly 2.9 amplifies market swings. The financial metrics are stark: gross margin is just 5.4%, operating and profit margins are negative (‑1.9% and ‑0.9% respectively), and trailing EPS is –35.27, with no EBITDA or forward earnings projected. The price‑to‑book ratio of 1.65 exceeds the industry’s average PE of 16.8 (which is undefined for GSIW), and the max drawdown of –97% underscores a history of severe loss. Finally, the Fear‑Greed Index sits at 89.86, labeled “Extreme Greed,” indicating that market sentiment may be overly optimistic despite the weak fundamentals.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD signal with negative histogram
  • High volatility (61%) and high beta (~2.9)
  • Severe historical drawdown (-97%)

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Favorable SMA hierarchy (20 > 50 > 200)
  • Neutral RSI (≈54) indicating no immediate overbought pressure
  • Stable but low volume limiting upside potential

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Persistent negative profitability and cash flow
  • High market risk factors (volatility, beta, drawdown)
  • Lack of dividend and uncertain growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth414.60%
Profit Margin-93.20%
ROE-56.35%
ROA-31.39%
Debt/Equity0.71
P/B Ratio1.6
Op. Cash Flow$-3751679
Industry P/E16.8

Technical Analysis

TrendBullish
RSI54.0
Support$25.40
Resistance$33.50
MA 20$30.29
MA 50$28.09
MA 200$27.38
MACDBearish
VolumeStable
Fear & Greed Index89.86

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta2.90
Volatility61.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.